A Phase 1 interventional study of Nalmefene + 0.94% MgCl2 and Nalmefene + 0.94% MgCl2 in Opioid Overdose, sponsored by Knoa Pharma LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-05.
Sponsored by Knoa Pharma LLC · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Opiate Overdose with a site in United States — 8 open to participants now, 15 under way, none of them phase 3. Opiate Overdose · United States.
Among the 56 studies in Opiate Overdose with a site in United States, this one is the 41st largest by enrollment of the 44 interventional ones that give a count, is one of 2 that started in 2026, is one of 6 in phase 1, and was the 56th registered.
70 studies on the registry are indexed under Opiate Overdose; 11 are open to participants now.
Browse Opiate Overdose studies →8 of the 56 studies in Opiate Overdose with a site in United States are open now. Recruiting first, the newest first:
University of Alabama at Birmingham · Sites in United States
Ages 19+
University of Illinois at Chicago · Sites in United States
Ages 18+ · Healthy volunteers
Drexel University · Sites in United States
Ages 18+ · Healthy volunteers
University of Washington · Sites in United States
Ages 18+
Hartford Hospital · Sites in United States
Ages 21–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Opiate Overdose studies recruiting now, 6 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 184 across 48 interventional studies indexed under Opiate Overdose.
Median enrollment 184 across the 44 interventional studies, 106 across the 12 observational. Of the 35 that completed or were terminated, 15 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 56 have an industry lead sponsor. The 10 most frequent:
This study is registered under Knoa Pharma LLC, one of the names counted as Knoa Pharma. Under that name alone:
Knoa Pharma LLC is the lead sponsor of 3 studies on the registry; none are open to participants now.
Knoa Pharma has 3 studies filed under Opiate Overdose — fewer than ten, so there is no comparison to draw.
1 of the studies in Opiate Overdose with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05713695University of Massachusetts, WorcesterSupporting Treatment Access and Recovery Through Linkage and Support | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 56 studies in Opiate Overdose with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to characterize the PK of nalmefene following IV bolus and IM injections using nalmefene 0.5 mg (0.94% MgCl2) and IV bolus of 0.5 mg nalmefene hydrochloride injection in healthy subjects.
Key Inclusion criteria:
Key Exclusion criteria:
Other inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nalmefene + 0.94% MgCl2 (IV)
Drug: Nalmefene + 0.94% MgCl2
Nalmefene + 0.94% MgCl2 (IM)
Drug: Nalmefene + 0.94% MgCl2
Nalmefene Hydrochloride injection
Drug: Nalmefene Hydrochloride Injection
Drug pages: Nalmefene · Magnesium Chloride
Nalmefene 0.5 mg + 0.94% MgCl2 for IV (bolus) administration
Drug pages: Nalmefene · Magnesium Chloride
Nalmefene 0.5 mg + 0.94% MgCl2 for IM administration
Nalmefene Hydrochloride Injection 0.5 mg for IV (bolus) administration
Area Under the Curve (AUC0-2.5)
Partial area under the plasma concentration-time curve from time zero to 2.5 minutes following nalmefene 0.5 mg (0.94% MgCl2) IV bolus administration and nalmefene hydrochloride injection 0.5 mg IV bolus administration
Time frame: 2.5 minutes post-dose
Area Under the Curve (AUC0-5)
Partial area under the plasma concentration-time curve from time zero to 5 minutes following nalmefene 0.5 mg (0.94% MgCl2) IV bolus administration and nalmefene hydrochloride injection 0.5 mg IV bolus administration
Time frame: 5 minutes post-dose
Area Under the Curve (AUC0-10)
Partial area under the plasma concentration-time curve from time zero to 10 minutes following nalmefene 0.5 mg (0.94% MgCl2) IV bolus administration and nalmefene hydrochloride injection 0.5 mg IV bolus administration
Time frame: 10 minutes post-dose
Area Under the Curve (AUC0-15)
Partial area under the plasma concentration-time curve from time zero to 15 minutes following nalmefene 0.5 mg (0.94% MgCl2) IV bolus administration and nalmefene hydrochloride injection 0.5 mg IV bolus administration
Time frame: 15 minutes post-dose
Area Under the Curve (AUC0-20)
Partial area under the plasma concentration-time curve from time zero to 20 minutes following nalmefene 0.5 mg (0.94% MgCl2) IV bolus administration and nalmefene hydrochloride injection 0.5 mg IV bolus administration
Time frame: 20 minutes post-dose
Area Under the Curve (AUC0-30)
Partial area under the plasma concentration-time curve from time zero to 30 minutes following nalmefene 0.5 mg (0.94% MgCl2) IV bolus administration and nalmefene hydrochloride injection 0.5 mg IV bolus administration
Time frame: 30 minutes post-dose
Area Under the Curve (AUCt)
Area under the plasma concentration-time curve from time zero to the time of last measurable concentration following nalmefene 0.5 mg (0.94% MgCl2) IV bolus administration and nalmefene hydrochloride injection 0.5 mg IV bolus administration
Time frame: Up to 48 hours post-dose
Area Under the Curve (AUCinf)
Area under the plasma concentration-time curve from time zero to infinity following nalmefene 0.5 mg (0.94% MgCl2) IV bolus administration and nalmefene hydrochloride injection 0.5 mg IV bolus administration
Time frame: Up to 48 hours post-dose
Maximum Plasma Concentration (Cmax)
Maximum plasma concentration of nalmefene following nalmefene 0.5 mg (0.94% MgCl2) IV bolus administration and nalmefene hydrochloride injection 0.5 mg IV bolus administration
Time frame: Up to 48 hours post-dose
Area Under the Curve (AUC0-2.5)
Partial area under the plasma concentration-time curve from time zero to 2.5 minutes following nalmefene 0.5 mg (0.94% MgCl2) IV bolus administration and nalmefene 0.5 mg (0.94% MgCl2) IM administration
Time frame: 2.5 minutes post-dose
Area Under the Curve (AUC0-5)
Partial area under the plasma concentration-time curve from time zero to 5 minutes following nalmefene 0.5 mg (0.94% MgCl2) IV bolus administration and nalmefene 0.5 mg (0.94% MgCl2) IM administration
Time frame: 5 minutes post-dose
Area Under the Curve (AUC0-10)
Partial area under the plasma concentration-time curve from time zero to 10 minutes following nalmefene 0.5 mg (0.94% MgCl2) IV bolus administration and nalmefene 0.5 mg (0.94% MgCl2) IM administration
Time frame: 10 minutes post-dose
Area Under the Curve (AUC0-15)
Partial area under the plasma concentration-time curve from time zero to 15 minutes following nalmefene 0.5 mg (0.94% MgCl2) IV bolus administration and nalmefene 0.5 mg (0.94% MgCl2) IM administration
Time frame: 15 minutes post-dose
Area Under the Curve (AUC0-20)
Partial area under the plasma concentration-time curve from time zero to 20 minutes following nalmefene 0.5 mg (0.94% MgCl2) IV bolus administration and nalmefene 0.5 mg (0.94% MgCl2) IM administration
Time frame: 20 minutes post-dose
Area Under the Curve (AUC0-30)
Partial area under the plasma concentration-time curve from time zero to 30 minutes following nalmefene 0.5 mg (0.94% MgCl2) IV bolus administration and nalmefene 0.5 mg (0.94% MgCl2) IM administration
Time frame: 30 minutes post-dose
Area Under the Curve (AUCt)
Area under the plasma concentration-time curve from time zero to the time of last measurable concentration following nalmefene 0.5 mg (0.94% MgCl2) IV bolus administration and nalmefene 0.5 mg (0.94% MgCl2) IM administration
Time frame: Up to 48 hours post-dose
Area Under the Curve (AUCinf)
Area under the plasma concentration-time curve from time zero to infinity following nalmefene 0.5 mg (0.94% MgCl2) IV bolus administration and nalmefene 0.5 mg (0.94% MgCl2) IM administration
Time frame: Up to 48 hours post-dose
Maximum Plasma Concentration (Cmax)
Maximum plasma concentration of nalmefene following nalmefene 0.5 mg (0.94% MgCl2) IV bolus administration and nalmefene 0.5 mg (0.94% MgCl2) IM administration
Time frame: Up to 48 hours post-dose
Ran from Feb 2026 to primary completion in Apr 2026, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nalmefene · Magnesium Chloride